



SDI Review Form 1.6

Journal Name:	<u>British Journal of Medicine and Medical Research</u>
Manuscript Number:	2014_BJMMR_10473
Title of the Manuscript:	A Placebo-Controlled Trial of Folate with B12 in Patients with Schizophrenia with Residual Symptoms in Ethiopia using a Sequential Parallel Comparison Design
Type of the Article	Study Protocols

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Compulsory REVISION comments	<p>British Journal of Medicine and Medical Research 2014_BJMMR_10473</p> <p>Title: "A Placebo-Controlled Trial of Folate with B12 in Patients with Schizophrenia with Residual Symptoms in Ethiopia using a Sequential Parallel Comparison Design"</p> <p>This study is a randomized, sequential parallel comparison design for double-blind placebo vs fixed dose, 4-month trial of folate plus B12 as add-on therapy to reduce symptoms of schizophrenia.</p> <p>It is an interesting "study protocol" about an old discussed issue. In this case the originality consist of the Ethiopic population of schizophrenic patients. But it is only a "study protocol". Authors do not report any result. It should be published when Authors collect some result data, also preliminary data.</p> <p>In any case the methodology of the study is not so clear in the text. It seems a three arms double blind placebo controlled study along two phases. Authors should be more clear even if it is understandable by the figure 1.</p> <p>Has been the protocol approved by an Ethical Commettee? Authors should clarify.</p>	



SDI Review Form 1.6

<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments		

Reviewer Details:

Name:	Massimo Carlo Mauri
Department, University & Country	Clinical Psychiatry, Clinical Neuropsychopharmacology Unit, IRCCS Ospedale Maggiore Policlinico, Milan, Italy